Growth Metrics

Harvard Bioscience (HBIO) Total Debt (2016 - 2025)

Historic Total Debt for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to $34.0 million.

  • Harvard Bioscience's Total Debt fell 1027.79% to $34.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.0 million, marking a year-over-year decrease of 1027.79%. This contributed to the annual value of $37.0 million for FY2024, which is 107.49% up from last year.
  • Per Harvard Bioscience's latest filing, its Total Debt stood at $34.0 million for Q3 2025, which was down 1027.79% from $34.9 million recorded in Q2 2025.
  • Harvard Bioscience's 5-year Total Debt high stood at $49.3 million for Q3 2022, and its period low was $34.0 million during Q3 2025.
  • Over the past 5 years, Harvard Bioscience's median Total Debt value was $41.4 million (recorded in 2023), while the average stood at $41.3 million.
  • Its Total Debt has fluctuated over the past 5 years, first surged by 1238.5% in 2022, then crashed by 2191.4% in 2023.
  • Harvard Bioscience's Total Debt (Quarter) stood at $48.3 million in 2021, then decreased by 3.12% to $46.8 million in 2022, then fell by 21.91% to $36.6 million in 2023, then grew by 1.07% to $37.0 million in 2024, then dropped by 8.09% to $34.0 million in 2025.
  • Its Total Debt stands at $34.0 million for Q3 2025, versus $34.9 million for Q2 2025 and $36.0 million for Q1 2025.